Cargando…

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

BACKGROUND: Inhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD). OBJECTIVE: To investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by means of a multicentre, double-blind, randomised, pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kedor, Claudia, Listing, Joachim, Zernicke, Jan, Weiß, Anja, Behrens, Frank, Blank, Norbert, Henes, Joerg Christoph, Kekow, Joern, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Seipelt, Eva, Specker, Christof, Feist, Eugen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Adult Still’s disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392486/ https://www.ncbi.nlm.nih.gov/pubmed/32404342 http://dx.doi.org/10.1136/annrheumdis-2020-217155

Ejemplares similares

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
por: Nirmala, Nanguneri, et al.
Publicado: (2015)

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
por: Kedor, Claudia, et al.
Publicado: (2021)

A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis
por: Zernicke, Jan, et al.
Publicado: (2016)

Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study
por: Henes, Joerg C., et al.
Publicado: (2022)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
por: Schulze-Koops, Hendrik, et al.
Publicado: (2021)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020)

Aktueller Stand der Impfung gegen SARS-CoV-2
por: Iking-Konert, Christof, et al.
Publicado: (2021)

Impfung gegen SARS-CoV-2 bei entzündlich rheumatischen Erkrankungen: Empfehlungen der DGRh für Ärzte und Patienten
por: Specker, C., et al.
Publicado: (2021)

Adult-Onset Still’s Disease
por: Mitrovic, Stéphane, et al.
Publicado: (2019)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

Mechanisms, biomarkers and targets for adult-onset Still’s disease
por: Feist, Eugen, et al.
Publicado: (2018)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany
por: Hasseli, Rebecca, et al.
Publicado: (2021)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

IgG4-related sialadenitis: IgG4 is helpful, but biopsies are still crucial
por: Witte, Torsten, et al.
Publicado: (2015)

Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach
por: Tomaras, Stylianos, et al.
Publicado: (2021)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
por: Kudela, Holger, et al.
Publicado: (2019)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Good jews/bad jews: thingified semites?
por: Younes, Anna-Esther
Publicado: (2021)

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

Accelerating HIV vaccine development through meaningful engagement of local scientists and communities
por: Chinyenze, Kundai, et al.
Publicado: (2023)

Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development
por: Haynes, Barton F., et al.
Publicado: (2023)

Generating and measuring effective vaccine-elicited HIV-specific CD8(+) T cell responses
por: Borgo, Gina M., et al.
Publicado: (2023)

‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
por: Stamatatos, Leonidas
Publicado: (2023)

Deutscher Rheumatologiekongress virtuell – erfolgreich tagen trotz Pandemie
por: Richter, Jutta G., et al.
Publicado: (2021)

Risk stratification for isolated tricuspid valve surgery: Still on the way
por: Chen, Jinmiao, et al.
Publicado: (2022)

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4kni7cdde3fmabb75nc5ogu601